Skip to main content
Signal8

Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc.

NYSE:PLXHealthcare
+0.50%$3.04
Mkt Cap$255.91M
EV-
Float81.19M
O/S84.32M
VOL1.16M sh
$ Vol$3.56M
RVOL1.18×
Inst Own19.1%
SI4.3%
Net Cash/Sh-
Dilution
Protalix BioTherapeutics, Inc. logoNYSE:PLX$3.04+0.50%
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›